(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $208.76
Išleistas: 26 bal. 2024 @ 22:56
Grąža: 0.07%
Ankstesnis signalas: bal. 26 - 17:13
Ankstesnis signalas:
Grąža: 1.91 %
Live Chart Being Loaded With Signals
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis...
Stats | |
---|---|
Šios dienos apimtis | 1.89M |
Vidutinė apimtis | 1.27M |
Rinkos kapitalizacija | 30.42B |
EPS | $0 ( 2024-04-24 ) |
Kita pelno data | ( $3.97 ) 2024-07-23 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 26.11 |
ATR14 | $11.62 (5.56%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Singhal Priya | Sell | 93 | Common Stock |
2024-04-01 | Murphy Nicole | Buy | 240 | Common Stock |
2024-04-01 | Murphy Nicole | Sell | 117 | Common Stock |
2024-04-01 | Murphy Nicole | Sell | 240 | Restricted Stock Unit |
2024-02-22 | Singhal Priya | Sell | 262 | Common Stock |
INSIDER POWER |
---|
4.52 |
Last 100 transactions |
Buy: 80 749 | Sell: 73 436 |
Tūris Koreliacija
Biogen Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
EVCM | 0.883 |
RBNC | 0.879 |
NLTX | 0.879 |
ACLX | 0.878 |
EGRX | 0.873 |
ARCT | 0.865 |
HBIO | 0.863 |
NATI | 0.862 |
FCFS | 0.861 |
MDLZ | 0.858 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
NYMTN | -0.908 |
WTRE | -0.908 |
RNMC | -0.903 |
REIT | -0.903 |
KBWD | -0.9 |
SDVY | -0.899 |
NEOG | -0.899 |
FFBW | -0.898 |
XT | -0.895 |
ICHR | -0.895 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Biogen Inc Koreliacija - Valiuta/Žaliavos
Biogen Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $9.84B |
Bruto pelnas: | $7.30B (74.24 %) |
EPS: | $8.02 |
FY | 2023 |
Pajamos: | $9.84B |
Bruto pelnas: | $7.30B (74.24 %) |
EPS: | $8.02 |
FY | 2022 |
Pajamos: | $10.17B |
Bruto pelnas: | $7.90B (77.61 %) |
EPS: | $20.97 |
FY | 2021 |
Pajamos: | $10.98B |
Bruto pelnas: | $8.87B (80.79 %) |
EPS: | $10.44 |
Financial Reports:
No articles found.
Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.